The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
HIV Infection and Cardiovascular Disease
Open accessAbstract
HIV infection has been considered as one of the major global public health threats of the last century, increasing several times the mortality rate in comparison to the cholera epidemic that swept London in the nineteenth century. Unlike the contamination caused by cholera bacillus, prevention of HIV infection requires other interventions than basic sanitation, and the antiretroviral agents currently remain the touchstone to transform the disease from subacute into a chronic condition. The introduction of highly active antiretroviral therapy (HAART) in the treatment of HIV-infected patients, in 1990s, has allowed better health status and greater longevity among people living with HIV, associated with a reduction in the viral transmission rate. For a while, it has been believed that universal access to HAART and the progressive increase in the efficiency of the prevention methods could save future generations [1]. However, it requires an enormous effort to expand HIV testing, maintenance of sustained treatment, and implementation of prevention programs. Nevertheless, HAART is not free of adverse effects. With the significant reduction of the mortality and morbidity associated with HIV induced immunodeficiency in patients using HAART, the HIV infection is behaving as a long-term sickness [2]. HIV infection and its treatment have been associated with abnormal metabolic profile [3]; increased prevalence of noncommunicable diseases [4, 5] and mortality rate of AIDS-related have shifted to non-AIDS-related conditions [6, 7]. In the pre-HAART era, mortality from cardiovascular disease in infected persons occurred almost two decades earlier than in the general population. After the introduction of HAART, this difference went on to about nine years [8]. Even though the HIV-infected population is getting older, most still ar less than 50 years old and, in the United States, only half of the population will be 50 years in 2015 [9]. Therefore, the long-term management of patients with HIV infection has to be expanded to diagnosis, treatment, and prevention of cardiovascular risk factors and coronary heart disease. Even so, most current guidelines for the treatment of HIV infection are still focused only on antiretroviral treatment and do not take into account the treatment and prevention of comorbidities not related to AIDS [10–12]. However, bringing the paradigm of cardiovascular disease prevention for the scenario of HIV infection requires detection of the prevalence of cardiovascular risk factors and coronary heart disease in HIV-infected patients. In this edition of this journal, a portrait of the Brazilian scenario of cardiovascular disease among HIV-infected patients was presented. Brazil is a country that has provided free access to HIV treatment for the entire population of infected people in the last two decades, and the use of HAART had a great impact on the costs of health care and the demand for the public health system. D. V. Araujo et al. showed that, in the last five years, the number of HIV/AIDS cases increased approximately by 40%, among patients under 50-years of age, yet the hospital admissions due to AIDS remained stable. Conversely, there was a marked increase in the hospitalizations due to acute myocardial infarction. R. K. Lazzaretti et al. provided data on genetic basis for understanding the complexity of the dyslipidemia in HIV infection. They detected that single nucleotide polymorphisms in six candidate genes (APO B, APO A5, APO E, APO C3, SCAP, and LDLR) were associated with dyslipidemia, showing that genetic factors contribute to determining the lipid profile in HIV-infected individuals on antiretroviral therapy. Even so, there is a lack of robust evidence for prescribing agents to reduce dyslipidemia in HIV-infected patients. The new guidelines for cholesterol treatment highlighted the lack of randomized clinical trials on the potential benefits of statin therapy to reduce the risk of atherosclerotic cardiovascular disease in HIV-infected patients exceeding the risk of adverse events or drug interactions [13]. Another approach, previously described for the general population [14, 15], was to determine whether the association between consumption of alcoholic beverages and hypertension was modified by race in HIV-infected individuals. Among lifestyle characteristics, the consumption of large amounts of alcohol was independently associated with hypertension in white and nonwhite HIV-infected individuals. M. L. R. Ikeda et al. showed that there was an association of blood pressure with the frequency of consumption among the whites, while for nonwhite participants the amount of alcohol consumed was more important than the pattern of consumption in raising blood pressure. Although some of lifestyle characteristics are not modifiable, alcohol consumption is suitable for intervention. In an attempt to compare some tools available to assess the overall cardiovascular risk profile of
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., Huebner, R. E., Janoff, E. N., Justice, A. C., Kuritzkes, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590150 · Cited by 539
Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328336a150 · Cited by 384
Cited by
Selenium: environmental significance, pollution, and biological treatment technologies
Tan, L. C., Nancharaiah, Y. V., van Hullebusch, E. D., & Lens, P. N. L. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.05.005 · Cited by 469
Biosynthesis of Metal and Metal Oxide Nanoparticles
Jeevanandam, J., Chan, Y. S., & Danquah, M. K. (2016) · ChemBioEng Reviews · doi:10.1002/cben.201500018 · Cited by 374
Metadata
- Authors
- Fuchs, S. C., Beltrami-Moreira, M., Oyeledun, B., Sow, P. S., & Vitoria, M.
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 2013
- Issue
- 1
- ISSN
- 1537-744X (ISSN-L)
- 2356-6140
- OpenAlex
- W2043843501
- Cited by
- 191
- References
- 2
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV Infection and Cardiovascular Disease. https://app.cochat.ai/papers/10.1155/2013/252463
- The paper
- Fuchs, S. C., Beltrami-Moreira, M., Oyeledun, B., Sow, P. S., & Vitoria, M. (2013). HIV Infection and Cardiovascular Disease. The Scientific World Journal. https://doi.org/10.1155/2013/252463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.